| Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease G Mocci, M Marzo, A Papa, A Armuzzi, L Guidi Journal of Crohn's and Colitis 7 (10), 769-779, 2013 | 172 | 2013 |
| Management of perianal fistulas in Crohn’s disease: an up-to-date review M Marzo, C Felice, D Pugliese, G Andrisani, G Mocci, A Armuzzi, L Guidi World Journal of Gastroenterology: WJG 21 (5), 1394, 2015 | 144 | 2015 |
| Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants G Andrisani, D Frasca, M Romero, A Armuzzi, C Felice, M Marzo, ... Journal of Crohn's and Colitis 7 (4), 301-307, 2013 | 109 | 2013 |
| Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects A Papa, F Scaldaferri, S Danese, S Guglielmo, I Roberto, M Bonizzi, ... Digestive Diseases 26 (2), 149-155, 2008 | 98 | 2008 |
| Faecal calprotectin assay after induction with anti-tumour necrosis factor α agents in inflammatory bowel disease: prediction of clinical response and mucosal healing at one year L Guidi, M Marzo, G Andrisani, C Felice, D Pugliese, G Mocci, O Nardone, ... Digestive and Liver Disease 46 (11), 974-979, 2014 | 92 | 2014 |
| Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver LR Lopetuso, G Mocci, M Marzo, F D’Aversa, GL Rapaccini, L Guidi, ... International journal of molecular sciences 19 (8), 2199, 2018 | 90 | 2018 |
| Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents A Papa, C Felice, M Marzo, G Andrisani, A Armuzzi, M Covino, G Mocci, ... Journal of Crohn's and Colitis 7 (2), 113-119, 2013 | 90 | 2013 |
| Use of infliximab in particular clinical settings: management based on current evidence A Papa, G Mocci, M Bonizzi, C Felice, G Andrisani, I De Vitis, L Guidi, ... Official journal of the American College of Gastroenterology| ACG 104 (6 …, 2009 | 53 | 2009 |
| SICUS and CEUS imaging in Crohn’s disease: an update G Mocci, V Migaleddu, F Cabras, D Sirigu, D Scanu, G Virgilio, M Marzo Journal of ultrasound 20, 1-9, 2017 | 52 | 2017 |
| FOXP3+ T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti‐TNFα Agents L Guidi, C Felice, A Procoli, G Bonanno, E Martinelli, M Marzo, G Mocci, ... BioMed research international 2013 (1), 286368, 2013 | 49 | 2013 |
| Disease patterns in late-onset ulcerative colitis: results from the IG-IBD “AGED study” W Fries, A Viola, N Manetti, I Frankovic, D Pugliese, R Monterubbianesi, ... Digestive and Liver Disease 49 (1), 17-23, 2017 | 47 | 2017 |
| Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab A Favale, S Onali, F Caprioli, D Pugliese, A Armuzzi, FS Macaluso, ... Inflammatory bowel diseases 25 (11), 1805-1812, 2019 | 42 | 2019 |
| Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) G Fiorino, F Caprioli, M Daperno, F Mocciaro, M Principi, A Viscido, ... Digestive and Liver Disease 51 (5), 632-639, 2019 | 42 | 2019 |
| An objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients' failure to TNF-alpha inhibitors S Onali, D Pugliese, FA Caprioli, A Orlando, L Biancone, OM Nardone, ... Official journal of the American College of Gastroenterology| ACG 117 (8 …, 2022 | 40 | 2022 |
| Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study D Pugliese, M Daperno, G Fiorino, E Savarino, E Mosso, L Biancone, ... Digestive and Liver Disease 51 (7), 972-977, 2019 | 40 | 2019 |
| Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel … A Tursi, L Allegretta, N Buccianti, ND Valle, W Elisei, G Forti, R Faggiani, ... Journal of Gastrointestinal & Liver Diseases 26 (3), 2017 | 35 | 2017 |
| Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study D Pugliese, G Privitera, F Crispino, N Mezzina, F Castiglione, G Fiorino, ... Alimentary pharmacology & therapeutics 56 (1), 95-109, 2022 | 33 | 2022 |
| COVID-19 vaccination willingness and hesitancy in patients with inflammatory bowel diseases: analysis of determinants in a national survey of the Italian IBD patients’ association A Costantino, D Noviello, FS Conforti, M Aloi, A Armuzzi, F Bossa, F Ficari, ... Inflammatory Bowel Diseases 28 (3), 474-478, 2022 | 33 | 2022 |
| Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: a multicenter, observational study in primary inflammatory bowel disease … A Tursi, G Mocci, R Faggiani, L Allegretta, N Della Valle, A de Medici, ... European journal of internal medicine 66, 85-91, 2019 | 30 | 2019 |
| Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers A Tursi, W Elisei, R Faggiani, L Allegretta, N Della Valle, G Forti, ... Medicine 97 (34), e11897, 2018 | 30 | 2018 |
